Development of interstitial pneumonia in a patient with rheumatoid arthritis induced by isoniazid for tuberculosis chemoprophylaxis

Rheumatol Int. 2012 May;32(5):1375-7. doi: 10.1007/s00296-010-1441-2. Epub 2010 Mar 27.

Abstract

Here, we report a 56-year-old patient with rheumatoid arthritis (RA) who had been treated with methotrexate and sulfuasalazine, but the disease activity remained high. Therefore, we planned TNF-blocker treatment for this patient. A tuberculin skin test was positive, we started anti-tuberculosis (TB) chemoprophylaxis with isoniazid (INH). However, liver dysfunction was appeared after 2 weeks from the start of INH. Therefore, we discontinued INH transiently and tried the desensitization of INH. However, interstitial pneumonia was developed 2 weeks after the re-start of INH, we decided to stop the INH prophylaxis. Interstitial pneumonia was improved by corticosteroid treatments. This case report shows that INH-induced IP can be occurred during the course of anti-TB chemoprophylaxis in patients with RA.

Publication types

  • Case Reports

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Antitubercular Agents / adverse effects*
  • Arthritis, Rheumatoid / complications
  • Arthritis, Rheumatoid / diagnosis
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / immunology
  • Biopsy
  • Chemical and Drug Induced Liver Injury / etiology
  • Humans
  • Immunosuppressive Agents / adverse effects*
  • Isoniazid / adverse effects*
  • Lung Diseases, Interstitial / chemically induced*
  • Lung Diseases, Interstitial / diagnosis
  • Lung Diseases, Interstitial / drug therapy
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Severity of Illness Index
  • Tomography, X-Ray Computed
  • Treatment Outcome
  • Tuberculin Test
  • Tuberculosis / diagnosis
  • Tuberculosis / etiology
  • Tuberculosis / prevention & control*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Adrenal Cortex Hormones
  • Antitubercular Agents
  • Immunosuppressive Agents
  • Tumor Necrosis Factor-alpha
  • Isoniazid